Cytosorbents Corp(CTSO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.8 | Insider Own | - | Shs Outstand | 3.1M | Perf Week | -17.01% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 79.55% | Insider Trans | - | Shs Float | - | Perf Month | -11.53% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.9 | Inst Own | - | Short Float | - | Perf Quarter | -22.51% |
| Income | -0.02B | P/S | 0.54 | EPS this Y | -69.23% | Inst Trans | -0.82% | Short Ratio | 8.29 | Perf Half Y | -56.07% |
| Sales | 0.04B | P/B | - | EPS next 5Y | - | ROA | -42.38% | Short Interest | 0.11M | Perf YTD | -50.17% |
| Book/sh | -0.24 | P/C | 4.55 | EPS past 3/5Y | 44.07% 8.18% | ROE | -336.19% | 52W High | -68.77% ($20.40) | Perf Year | -66.31% |
| Cash/sh | 1.4 | P/FCF | - | Sales past 3/5Y | 2.23% -2% | ROIC | -130.68% | 52W Low | 6.17% ($6.00) | Perf 3Y | -86.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -61.01% | Gross Margin | 71.61% | Volatility(W/M) | 19.07% 13.06% | Perf 5Y | -96.43% |
| Dividend TTM | - | EV/Sales | 1.23 | Sales Y/Y TTM | 8.64% | Oper. Margin | -31.6% | ATR (14) | 0.85 | Perf 10Y | -93.94% |
| Dividend Ex-Date | - | Quick Ratio | 0.5 | EPS Q/Q | -342.6% | Profit Margin | -48.94% | RSI (14) | 41.2 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.66 | Sales Q/Q | 0.17% | SMA20 | -9.5% ($7.04) | Beta | 1.32 | Target Price | $47.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -13.16% ($7.34) | Rel Volume | 1.14 | Prev Close | $6.33 |
| Employees | 129 | LT Debt/Eq | - | EPS/Sales Surpr. | -11.11% 2.64% | SMA200 | -43.07% ($11.19) | Avg Volume(3M) | 0.01M | Price | $6.37 |
| IPO | 2006/8/8 | Option/Short | Yes/Yes | Trades | 1396 | Volume | 14,880 | Change | 0.63% |
Company
CTSO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩸 This company develops advanced medical devices that purify the blood of ICU and cardiac surgery patients outside the body. Its flagship product, CytoSorb, directly removes excess inflammatory substances and toxins from the blood, reducing the risk of organ failure and has been used in over 300,000 treatments worldwide. The company is also a blood purification specialist currently pursuing FDA approval for its antithrombotic removal device (DrugSorb-ATR).
Over the past 1 year, on the lower side
69% below its 1-year high.
CTSO has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -69.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -86.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
MSSM 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $20M.
CTSO $20M PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is CTSO?
CTSO belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CTSO?
The market cap of CTSO is approximately $20M, ranking 5,279 within its sector.
What is the 52-week high and low for CTSO?
CTSO has recorded a 52-week high of $20.40 and a low of $6.00.
